Results 81 to 90 of about 2,631,955 (205)

DataSheet1_USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma.docx

, 2021
Colon adenocarcinoma (COAD) is one of the diseases with the highest morbidity and mortality in the world. At present, immunotherapy has become a valuable method for the treatment of COAD.
Xuxu Liu (11130591), Biao Ma (260101), Dongbo Xue (22386), Long Li (6555), Yuanyuan Sun (505629), Wenchao Yao (8545611), Yang Yang (45629)   +6 more
core   +1 more source

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma

EBioMedicine, 2018
TP53 has been proved to be associated with cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied.
Wenjing Xiao, Nan Du, Taoyuan Huang, Jinan Guo, Xingkui Mo, Tao Yuan, Yong Chen, Ting Ye, Chunwei Xu, Wenxian Wang, Guoqiang Wang, Shangli Cai, Jing Chen   +12 more
doaj   +1 more source

Additional file 2 of The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma

, 2022
Additional file 2: Supplementary Figure 2.
Dong Dong (23216), Heng Wang (76752), Wei Wang (17594), Liang Chen (73736), Tianyi Liu (3598988)   +4 more
core   +1 more source

Strength of selection in lung tumors correlates with clinical features better than tumor mutation burden. [PDF]

Sci Rep
Single nucleotide substitutions are the most common type of somatic mutations in cancer genome. The goal of this study was to use publicly available somatic mutation data to quantify negative and positive selection in individual lung tumors and test how ...
Gorlov IP, Gorlova OY, Tsavachidis S, Amos CI.   +3 more
europepmc   +2 more sources

Image_1_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Figure S3 from Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression

, 2023
Supplementary Fig. S3 shows analysis of lung tumor burden and tumor cell proliferation/death in the Kras; p53 model with Keap1/Nrf2 mutation.
Justin R. Prigge (16016027), Gina M. DeNicola (14957366), Aimee Falzone (15386904), Iok In Christine Chio (15136553), Janine M. DeBlasi (16016024), Nicolas Prieto-Farigua (15386907), Edward E. Schmidt (16016030), Samantha Caldwell (15386910), Florian A. Karreth (14956749)   +8 more
core   +1 more source

Machine learning-driven estimation of mutational burden highlights DNAH5 as a prognostic marker in colorectal cancer

Biology Direct
Background Tumor Mutational Burden (TMB) have emerged as pivotal predictive biomarkers in determining prognosis and response to immunotherapy in colorectal cancer (CRC) patients.
Yangyang Fang, Tianmei Fu, Qian Zhang, Ziqing Xiong, Kuai Yu, Aiping Le   +5 more
doaj   +1 more source

Mutational Landscape of FGFR4 Across Malignancies: A Cross-Cancer Analysis of the AACR Project GENIE Database

Current Issues in Molecular Biology
Background/Aim: Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine kinase involved in cell growth, proliferation, and angiogenesis. While FGFR1–3 are well studied in cancer, FGFR4 remains relatively understudied, and the distribution of its ...
Henna Ali, Tyler Gengnagel, Salem Birkholz, Gowri Vadmal, Elijah Torbenson, Beau Hsia, Abubakar Tauseef, Peter T. Silberstein   +7 more
doaj   +1 more source

Image_5_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Image1_Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.TIF

, 2022
Ovarian cancer (OC), one of the most common malignancies of the female reproductive system, is characterized by high incidence and poor prognosis. Tumor mutation burden (TMB), as an important biomarker that can represent the degree of tumor mutation, is ...
Siyuan Shen (649230), Hua Jin (320594), Mengjing Cui (3125808), Wenjing Yan (1918651), Xing Zhang (11943), Shuqian Xie (11101006), Dan Meng (124143), Qianqian Xia (708901), Shizhi Wang (337117)   +8 more
core   +1 more source